WO2018175774A1 - Cell yield for synthetic tissue controls and synthetic tissue microarray controls - Google Patents
Cell yield for synthetic tissue controls and synthetic tissue microarray controls Download PDFInfo
- Publication number
- WO2018175774A1 WO2018175774A1 PCT/US2018/023840 US2018023840W WO2018175774A1 WO 2018175774 A1 WO2018175774 A1 WO 2018175774A1 US 2018023840 W US2018023840 W US 2018023840W WO 2018175774 A1 WO2018175774 A1 WO 2018175774A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- cultured
- cell
- culturing
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/36—Embedding or analogous mounting of samples
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2535/00—Supports or coatings for cell culture characterised by topography
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N2001/2893—Preparing calibration standards
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/36—Embedding or analogous mounting of samples
- G01N2001/368—Mounting multiple samples in one block, e.g. TMA [Tissue Microarrays]
Definitions
- Control samples are often used to maintain quality control (QC) for reproducibility of test results by immunohistochemical (IHC) staining, in situ hybridization (ISH), and other methods of molecular analyses.
- IHC immunohistochemical
- ISH in situ hybridization
- Some of the controls available for IHC staining and ISH staining of tumor tissues and other diseased tissues are cancer tissue-derived controls. However such types of controls are only available in very limited quantities, and once such controls are exhausted, replacement controls with the same characteristics may be unavailable.
- Other types of available controls are cancer cell lines-derived controls. However, such types of controls do not exhibit consistent patterns and levels of cellular expression of a given marker, or heterogeneity of said expression, which is ubiquitous to tumor tissues. As such, these controls have little or no morphological resemblance to actual tumor tissues. Further, conventional techniques to form controls involve processes that produce poor yield, thereby requiring significant amounts of cultured cells in order to form such controls, thereby increasing productivity costs and decreasing productivity efficiency.
- the disclosed embodiments provide methods for forming synthetic tissue controls and synthetic tissue microarray controls for IHC and ISH tests for cancer diagnosis and prognosis, as well as methods for determining presence of one or more types of cancer.
- a method for determining presence of at least one type of cancer includes staining a portion of a synthetic tissue control (STC).
- STC includes normal cells and cancer cells of a type of cancer co-cultured based on at least one cell culturing factors.
- the at least one co-culture factors includes one or more of the following factors: A type of the cancer cell being cultured, a ratio of the cancer cells to the normal cells being co-cultured, seeding density of the cells being cultured, a type of cell growth supplement used to facilitate co-culturing the cells, and a concentration of the cell growth supplement used to facilitate co-culturing the cells.
- the method further includes observing the stained portion of the STC to determine a presence of one or more biomarker types, the one or more biomarker types indicating presence of the cancer cells.
- a method to form a synthetic tissue control for use in determining presence of cancer includes culturing cells comprising normal cells and cancer cells of a type of cancer based on at least one cell culturing factors.
- the at least one cell culturing factors includes a type the cancer cells being cultured, a ratio of the cancer cells to the normal cells being cultured, and seeding density of the cells being cultured.
- a synthetic tissue microarray includes a plurality of STCs, each STC of the plurality of STCs includes normal cells and cancer cells of a type of cancer.
- the normal cells and the cancer cells are cultured based on at least one cell culturing factors.
- the at least one cell culturing factors includes a type of the cancer cells being cultured, a ratio of the cancer cells to the normal cells being cultured, seeding density of the normal cells and cancer cells being cultured, and a type of cell growth supplement used to facilitate culturing and growth of the normal cells and cancer cells.
- FIG. 1 is an illustration of a synthetic tissue microarray that includes four controls in accordance with one embodiment.
- FIG. 2A illustrates a side view of a fluidly gel being solidified to form a cell holder in accordance with one embodiment.
- FIG. 2B illustrates a side view of the cell holder of FIG. 2A having a cavity in the cell holder in accordance with one embodiment.
- FIG. 2C illustrates a top down view of the cell holder of FIG. 2A in accordance with one embodiment.
- FIG. 2D illustrates another top down view of the cell holder of FIG. 2A having a dye applied to co-cultured cells deposited into the cavity in accordance with one embodiment.
- FIG. 3 A illustrates an image of synthetic tissue containing breast cancer cells, which has been stained with a specific antibody to HER-2/nue to illustrate presence of HER-2/nue expression in accordance with one embodiment.
- FIG. 3B illustrates an image of breast tumor tissue, which has been stained with a specific antibody to HER-2/nue to illustrate presence of HER-2/nue expression in accordance with one embodiment.
- FIG. 3C illustrates an image of the synthetic tissue of FIG. 3A which has been stained with pre-absorbed antibody HER-2/nue as a test of specificity of the stain in accordance with one embodiment.
- FIG. 3D illustrates an image of the breast tumor tissue of FIG. 3B which has been stained with pre-absorbed antibody HER-2/nue as a test of specificity of the stain in accordance with one embodiment.
- FIG. 4A illustrates an image of synthetic tissue stained to illustrate presence of E Cadherin marker in accordance with one embodiment.
- FIG. 4B illustrates an image of breast tumor tissue stained to illustrate presence of E Cadherin marker in accordance with one embodiment.
- FIG. 4C illustrates an image of synthetic tissue stained to illustrate presence of Estrogen Receptor marker in accordance with one embodiment.
- FIG. 4D illustrates an image of breast tumor tissue stained to illustrate presence of Estrogen Receptor marker in accordance with one embodiment.
- FIG. 4E illustrates an image of synthetic tissue stained to illustrate presence of a cell proliferation (Ki-67) marker in accordance with one embodiment.
- FIG. 4F illustrates an image of breast tumor tissue stained to illustrate presence of a cell proliferation (Ki-67) marker in accordance with one embodiment.
- FIG. 5 illustrates examples of antibodies for detecting different types of cancers that are covered by the synthetic tissue controls and the synthetic tissue microarrays described herein, in accordance with one embodiment.
- a 3-D Synthetic tissue control is generated by co-culturing normal cells and a type of cancer cells under defined and controlled conditions in suspension.
- normal cells include any non-tumor cells. Normal cells may be formed from stromal cells and other suitable cell types.
- the STC reproducibly exhibits expected patterns and levels of tumor tissue associated cellular and extracellular (ECM) markers and architecture with close resemblance to tumor tissue. Examples of the close resemblance between STCs and tumor tissues are illustrated in FIGs. 3 A- 3D and FIGs. 4A-4E.
- 3-D Synthetic tissue microarray controls (STMC) are constructed from multiple STCs.
- STC and STMC are prepared as formalin-fixed and paraffin-embedded (FFPE) blocks or precut into sections for various markers used in pathology testing laboratories. Examples of compatible markers include various markers discussed in detail in the below description, as well as illustrated in the figures.
- the STC and STMC blocks and sections can be used as both positive and negative controls for IHC staining and ISH staining of tumor tissue and other diseased tissues.
- the processes for forming STCs and STMCs and using the STCs and STMCs to detect presence of cancer are provided in detail in the paragraphs below.
- STCs are cultured in an approximately zero gravity culture, usually in the form of a formalin-fixed and paraffin-embedded (FFPE) cell block, where each STC contains a type of cancer cells and stromal cells.
- cancer cells and normal stromal cells are separately cultured in cell-culture flasks.
- a DNase of approximately 5 microgram per milliliter of cell culture medium is added to each cell-culture flask that contains either cancer cells or normal stromal cells. The addition of DNase prevents clumping of the harvested cancer cells or normal stromal cells from the cell-culture flasks. As a result, cell counts of the cancer cells and/or the normal stromal cells may be accurately determined and un-clumped cancer cells and normal stromal cells may be harvested.
- two or more cell-types are co-cultured under stringently defined conditions and within a controlled environment.
- the cancer cells and the stromal cells are co-cultured in a plurality of cell culture bags of cells.
- a cell culture bag is a container having a built-in port for adding and removing cells.
- the cell culture bag is sterile.
- the build-in port of the cell culture bag includes an air tight cap. The bag holds cancer and stromal cells during the co-culture stage of production.
- approximately 80 million stromal cells and/or cancer cells may be harvested from each cell culture bag after approximately ten days of co-culturing. In other embodiments, approximately 30-120 million stromal cells and/or cancer cells may be harvested from each cell culture bag after approximately two weeks of co-culturing.
- the dimensions of the cell culture bags may vary based on the type of cells being co-cultured as well as the type of nutrients optimal for co-culturing such cells.
- a DNase of approximately 5 microgram per milliliter of cell culture medium is added to each cell culture bag containing cancer cells and normal stromal cells, where the cell culture bag is mounted on a bioreactor in a CC -incubator during the co-culturing process.
- the addition of the DNase facilitates cells to remain in an un-clumped condition in suspension during co-culture. More particularly, the addition of DNase facilitates the normal stromal cells to remain un-clumped, and thus allows the normal stromal cells to form a homogenous core. Further, the addition of DNase facilitates the cancer cells to remain un- clumped, and thus facilitates un-clumped cancer cells to invade the homogenous core.
- a Fibronectin of approximately 1 microgram per milliliter of the cell culture medium is added on the first day to co-culture in each cell culture bag containing the cancer cells and the normal stromal cells.
- Fibronectin facilitates formation of basement membrane-like structures during an early phase of growth of the co-culture cells. Further, the addition of the Fibronectin facilitates an improved contact between the co-cultured cancer cells and the normal stromal cells. The formation of the basement membrane-like structures facilitates the co-cultured cells to resemble actual tumor tissue.
- the cancer cells and the stromal cells are co-cultured in an approximately zero gravity environment for a period of eight to twelve days. Furthermore, the cancer cells and the stromal cells are co-cultured in a cell culture chamber configured to maintain a concentration of C0 2 and temperature inside and outside the chamber at levels based on at least one cell culturing factors to allow the cells to develop characteristics that are similar to or identical to actual tumor tissue.
- a motorized rotating device holds and slowly spins the cell culture chambers at a speed that is based on the at least one cell culturing factors to allow the cells to develop characteristics similar to or identical to characteristics of actual tumor tissue.
- Cell culturing factors include, but are not limited to, the type of cancer cells being cultured, the ratio of the cancer cells to the stromal cells, seeding density of the cells being cultured, and concentration and type of cell growth supplement used to facilitate culturing the cells to develop characteristics that are similar to or identical to actual tumor tissue.
- a ratio of the cancer cells for a breast cancer cell line (MCF.7) to the normal stromal cell (fibroblast) is 1 in 99.8, respectively, to produce the STC.
- 10 micrograms of insulin are used as a growth factor supplement to facilitate growth of the MCF 7.
- the seeding density of MCF.7 cancer cells is 18,750 per milliliter, whereas that of the fibroblast 187,876 per milliliter.
- STMCs are also cultured based on the above described process.
- STC and STMC are cultured based on one of the above-identified factors.
- STC and STMC are cultured based on two of the above-identified factors.
- STC and STMC are cultured based on three of the above-identified factors.
- STC and STMC are cultured based on all of the above-identified factors.
- STC and STMC are cultured, based on at least one of the previously stated cell culturing factors, to provide control 'faux' tissues having known patterns and levels of expression of various markers, including proteins, RNAs, DNAs and other components of interest, for diagnosis, prognosis, and selection of patients for a particular specific/targeted therapy.
- STC and STMC may be cultured for standard expression of markers employed in IHC as diagnostic and predictive markers for treatment response, exemplified by tests for Epidermal Growth Factor Receptor-2 (HER-2/nue), estrogen receptor (ER), progesterone receptor (PR), Ki-67, and other types of suitable diagnostic and predictive markers for treatment response.
- HER-2/nue Epidermal Growth Factor Receptor-2
- ER estrogen receptor
- PR progesterone receptor
- STC and STMC may further be cultured for standard expression of markers that are employed in IHC as predictive markers to treatment response, exemplified by tests for HER-2/nue, Met 4, as well as other types of suitable predictive markers for treatment response. Furthermore, STC and STMC may also be cultured or standard expression of markers employed in immunofluorescence techniques.
- STC and STMC may also be cultured to provide a consistent level of expression when observed via a fluorescence in situ hybridization (FISH) based technique for RNA and/or DNA markers.
- FISH fluorescence in situ hybridization
- the expression may include expression levels of RNA translocations.
- the expression may include expression levels of DNA mutations.
- STC and STMC may also be cultured to provide a consistent level of expression when observed via a chromogenic in situ hybridization (CISH) based technique for RNA and/or DNA markers.
- CISH chromogenic in situ hybridization
- the expression may include expression levels of RNA translocations and/or DNA mutations. As such, an almost limitless range of biomarkers may be provided by selection of cell lines that are employed to make the STC or STMC.
- STC and STMC may be cultured, based on at least one of the previously stated cell culturing factors, to consistently provide various levels of expressions of biomarkers used in IHC and ISH staining.
- STC and STMC are cultured to provide high expression (HE or 3+) of biomarkers used in IHC and ISH staining.
- STC and STMC are cultured to have medium expression (ME or 2+) of biomarkers used in IHC and ISH staining.
- STC and STMC are cultured to have low expression (LE or 1+) of biomarkers used in IHC and ISH staining.
- co-cultured cells from the plurality of cell culture bags are deposited into a centrifuge tube to mix the co-cultured cells and to combine the co-cultured cells for processing and embedding.
- the co- cultured cells product is tightly wrapped around in a biopsy filter paper and placed in a tissue processing equipment, such as the centrifuge or another processing equipment described herein.
- the cultured STC is processed and then embedded.
- a cell holding device having a cavity utilized to hold co-cultured cells from at least two cell culture bags is utilized to hold the co- cultured cells during the processing and the embedding of the co-cultured cells.
- the cell holding device is formed from a fluidly gel that solidifies at room temperature.
- the fluidly gel is placed in a reservoir having a shape that is similar to a desired shape of the fluidly gel once the fluidly gel solidifies.
- An object is inserted into the fluidly gel during the solidification of the fluidly gel and subsequently removed from the fluidly gel once the fluidly gel solidifies to form the cavity.
- the size and shape of the cavity are defined by an external shape and size of the object.
- different objects having different external sizes and shapes are utilized to form cavities having different sizes and shapes based on a desired amount of co-cultured cells to be processed, the type of the cancer cells to be processed, the quantity of desired STC, as well as other factors described herein.
- the cavity securely holds the co-cultured cells to prevent the co-cultured cells from dissipating into the surrounding medium during the processing and embedding processes described herein.
- the cavity is operable to hold co-culture cells harvested from two cell culture bags.
- the cavity is operable to store the co-cultured cells from additional cell culture bags, thereby further increasing the yield of desirable cell cores.
- a colored dye is added to the harvested co-cultured cell product. More particularly, a dye having a pre-determined color is added to the harvested co-cultured cell product without touching such product, thereby allowing the dye to remain confined within the cavity.
- a colored dye to the harvested co-cultured cell product prior to the harvested co- cultured cell product is embedded in paraffin facilitates an accurate means to identify the harvested co-cultured cell product.
- a filter material such as a biopsy filter paper is then wrapped around the cell holding device containing the harvested co-cultured cell product and the dye within its cavity.
- the cell holding device is then placed in a histological cassette and transferred onto a tissue processing tray. Additional processes, such as vacuum infiltration process and paraffin embedding process may then be performed on the harvested co- cultured cell product as a block.
- the harvested co-cultured cell product is fixed in formalin for subsequent processing and embedding.
- the harvested co-cultured cell product is fixed in bousin or another fixative solution for subsequent the processing and embedding.
- the cavity is operable to hold co-cultured cells harvested from at least two cell culture bags. Additional descriptions of the cell holding device, forming the cell holding device, and depositing co-cultured cells into the cavity of the cell holding device are provided in the paragraphs below and are illustrated in at least FIGS. 2A-2D.
- the diameter of the cultured STC is approximately 0.04Cm. In another embodiment, the diameter of the cultured STC may be within a range of 0.01-0.04Cm. Contrary to the STC, the tissue specimen may have a diameter of 2-4Cm. Given the size of the cultured STC, a processing and an embedding device having a mesh with pore size approximately 0.001cm is used to hold the tissue specimen during the embedding process. In another embodiment, the pore size of the embedding device is within a range of 0.001-0.004Cm. A plurality of cultured STCs that provide a desired level of expression of desired biomarkers is embedded to form a STMC.
- a section from each block of the embedded STC is evaluated by IHC staining techniques to identify individual constructs.
- the individual constructs in the embedded STC represent 50 to 60 % from the total of approximately 500 individual constructs with the desired combination of cancer cells and normal stromal cells and the invasion of normal stromal cell core by the cancer cells.
- the individual constructs in the embedded STC represent 80 % from the total of 500-600 individual constructs with the desired combination of cancer cells and normal stromal cells and the invasion of normal stromal cell core by the cancer cells.
- only constructs with characteristics that are similar or identical to actual tumor tissue are selected as STC.
- STMC Single constructs from each block containing a certain combination of co-cultured cell types with characteristics that are similar or identical to actual tumor tissue are mechanically removed from the original block and are used to construct a STMC.
- the STMC is constructed to include a plurality of types of cancer cells with varying levels and patterns of expression of markers of interest.
- the STC and STMC may be viewed by laboratory operators via a variety of devices such as microscopes, whole slide imaging (WSI) devices, and other suitable devices for observing expressions of biomarkers.
- FIG. 1 is an illustration of a synthetic tissue microarray 100 that includes four STCs 101,
- controls 101, 102, 103, and 104 in accordance with one embodiment.
- controls 101, 102, 103, and 104 are placed proximate to test tissue 105 on the same histologic slide.
- the controls 101, 102, 103, and 104 and the test tissue 105 are stained with one or more stains for different types of biomarkers.
- the synthetic tissue microarray 100 is stained to observe for expression of markers employed in IHC as diagnostic markers and predictive markers for treatment response. In other embodiments, the synthetic tissue microarray 100 is stained to observe for expression of markers employed in IHC as predictive markers for treatment response. In further embodiments, the synthetic tissue microarray 100 is stained and observed via a FISH technique, for a level of expression of RNA and DNA markers. In further embodiments, the synthetic tissue microarray 100 is stained and observed via a CISH technique, for a level of expression of RNA and DNA markers.
- the synthetic tissue microarray 100 provides positive controls for at least one type of cancer. In other embodiments, some controls of the synthetic tissue microarray 100 provide positive controls while other controls of the synthetic tissue microarray 100 provide negative controls.
- the synthetic tissue microarray 100 may be cultured to provide high expression, medium expression, or low expression of the markers. Although the embodiment illustrated in FIG. 1 includes four controls 101, 102, 103, and 104, the synthetic tissue microarray 100 may be formed from a different number of controls.
- a laboratory operator may examine the synthetic tissue microarray 100 under a variety of devices such as microscopes and WSI devices to compare the stained controls with the stained test tissue to determine presence or absence of expression of markers in test tumor tissues.
- FIG. 2A illustrates a side view of a fluidly gel 201 being solidified to form a cell holder 200 in accordance with one embodiment.
- the fluidly gel 201 is deposited proximate a cooling object 220 to cool the temperature of the fluidly gel 201, thereby solidifying the fluidly gel 201 to form the cell holder 200.
- the fluidly gel 201 is a solid at room temperature and is initially heated up such that the fluidly gel 201 is in a fluid state.
- the fluidly gel 201 is placed in a reservoir during the solidification process to take on a shape approximately defined by an internal surface of the reservoir.
- the cooling object 220 is ice that facilities cooling of the fluidly gel 201.
- FIG. 2B illustrates a side view of the cell holder 200 of FIG. 2A having a cavity 202 in the cell holder 200 in accordance with one embodiment.
- FIG. 2C illustrates another image of the cell holder 200 of FIG.
- FIGS. 2B and 2C illustrate one cavity 202 formed on the cell holder 200, multiple cavities, each operable to hold co-cultured cells from at least two cell culture bags may be formed on the cell holder 200. Further, although the cavity of FIG. 2C punctures through opposite surfaces of the cell holder 200, other cavities may not puncture through the cell holder 200. As described herein, the cavity 202 may take on a variety of shapes and dimensions, including the shape illustrated in FIGS. 2B and 2C.
- FIG. 2D illustrates another top down view of the cell holder 200 of FIG. 2 A having a dye applied to co-cultured cells 204 deposited into the cavity in accordance with one embodiment.
- a blue colored dye is applied to the co-cultured cells 204 that are deposited in the cavity 202.
- the amount of dye applied may be based on a variety of factors including the number of co-cultured cells deposited in the cavity 202, the type of cancer cells deposited in the cavity 202, the size and dimensions of the cavity 202 as well as other factors described herein.
- a pre-selected colored dye is carefully added to the co- cultured cells product within the cavity 202 to ensure that the colored dye remains confined within the cavity 202.
- FIG. 2D illustrates a blue dye applied in the cavity 202
- a different colored dye may also be applied to facilitate identification of the co-cultured cells.
- a filter material such as filter paper is applied over the cavity.
- the cell holder 200 is then transferred onto a pathology cassette (not shown) and the pathology cassette is processed to form STC.
- the STC is then embedded on a paraffin block to form a STMA.
- FIG. 3A illustrates an image of synthetic tissue containing breast cancer cells in accordance with one embodiment.
- FIG. 3B illustrates an image of breast tumor tissue in accordance with one embodiment.
- the synthetic tissue illustrated in FIG. 3A has been cultured under conditions described herein. As shown in FIGs. 3 A and 3B, the synthetic tissue containing breast cancer cells and the actual breast tumor tissues exhibit significantly similar characteristics.
- FIG. 3C illustrates an image of the synthetic tissue of FIG. 3 A after the synthetic tissue is stained with pre-absorbed antibody to HER-2/nue to illustrate a specificity of the stain for HER- 2/nue marker in accordance with one embodiment.
- FIG. 3D illustrates an image of the breast tumor tissue of FIG. 3B after the tumor tissue is stained with pre-absorbed antibody to HER-2/nue to illustrate a specificity of the stain for HER-2/nue marker in accordance with one embodiment. As shown in FIGs.
- the stained synthetic tissue and the stained tumor tissue exhibit significantly similar characteristics, which allow the synthetic tissue to be used as a control for standard expression of markers that are employed in IHC as a diagnostic marker or as a predictive marker for treatment response such as HER-2/nue.
- Other examples of expression of markers that are employed in IHC as predictive markers for treatment response include Met 4, as well as other suitable diagnostic markers or predictive markers for treatment response.
- the synthetic tissues illustrated in FIGs. 3 A and 3C may also provide a level of expression of RNA and DNA markers when observed via a FISH technique.
- the synthetic tissues illustrated in FIGs. 3 A and 3C may also provide a level of expression of RNA and DNA markers when observed via a CISH technique.
- FIG. 4A illustrates an image of synthetic tissue stained to illustrate presence of E Cadherin marker in accordance with one embodiment.
- FIG. 4B illustrates an image of breast tumor tissue stained to illustrate presence of E Cadherin marker in accordance with one embodiment.
- FIG. 4C illustrates an image of synthetic tissue stained to illustrate presence of Estrogen Receptor marker in accordance with one embodiment.
- FIG. 4D illustrates an image of breast tumor tissue stained to illustrate presence of Estrogen Receptor marker in accordance with one embodiment.
- FIG. 4E illustrates an image of synthetic tissue stained to illustrate presence of a proliferation (Ki-67) marker in accordance with one embodiment.
- FIG. 4F illustrates an image of breast tumor tissue stained to illustrate presence of a proliferation (Ki-67) marker in accordance with one embodiment.
- the synthetic tissues illustrated in FIGs. 4A, 4C, and 4E have been cultured under conditions described herein. As shown in FIGs. 4A - 4F, the synthetic tissues and the stained tumor tissues exhibit significantly similar characteristics, which allow the synthetic tissues to be employed in IHC as diagnostic markers and predictive markers for treatment response, exemplified by tests for E Cadherin, ER, progesterone receptor, and Ki-67, as well as tests for other suitable types of diagnostic markers and predictive markers for treatment response. In other embodiments, the synthetic tissues illustrated in FIGs. 4A, 4C, and 4E may also be used to provide for expressions of biomarkers employed in IHC as predictive markers for treatment response. In further embodiments, the synthetic tissues illustrated in FIGs.
- FIGs. 4A, 4C, and 4E may also provide a level of expression of RNA and DNA markers when observed via a FISH technique.
- the synthetic tissues illustrated in FIGs. 4A, 4C, and 4E may also provide a level of expression of RNA and DNA markers when observed via a CISH technique.
- FIG. 5 illustrates examples of antibodies for detecting different types of cancers that are covered by the synthetic tissue controls and the synthetic tissue microarray controls described herein, in accordance with one embodiment.
- STC and STMC can be used to test a variety of types of cancers including, but not limited to breast cancer, lung cancer, liver cancer, thyroid cancer, prostate cancer, colon cancer, cervical cancer, kidney cancer, ovarian cancer, melanoma cancer, brain cancer, leukemia, lymphomas as well as other types of cancers.
- a method to increase yield of co-cultured cells of a synthetic tissue control comprising solidifying a fluidly gel form a solid cell holder; forming a cavity in the cell holder to hold co-cultured cells, the cavity being operable to hold a plurality of cell culture bags of co-cultured cells, the co-cultured cells comprising normal cells and cancer cells of a type of cancer co-cultured based on at least one cell culturing factors, the at least one co-culture factors comprising a type of the cancer cells being co-cultured, a ratio of the cancer cells to the normal cells being co-cultured, seeding density of the normal cells and the cancer cells being co-cultured, a type of cell growth supplement used to facilitate co-culturing the normal cells and the cancer cells, and a concentration of the cell growth supplement used to facilitate co-culturing the normal cells and the cancer cells; depositing co-cultured cells from at least two of the plurality of the cell culture bags of co-cultured cells in the cavity
- Clause 2 the method of clause 1, further comprising applying an amount of dye to the cavity to identify the co-cultured cells deposited in the cavity during the processing of the co- cultured cells.
- Clause 3 the method of clause 1 or 2, further comprising determining the amount of dye to apply to the cavity based on a number of the co-cultured cells deposited in the cavity.
- Clause 4 the method of at least one of clauses 1-3, wherein forming the cavity in the cell holder comprises: inserting an object into the fluidly gel while the fluidly gel is solidifying, a portion of the object having a shape that defines the cavity; and removing the object once the fluidly gel has solidified to form the cavity.
- Clause 5 the method of at least one of clauses 1-4, further comprising embedding the synthetic tissue control on a paraffin block to form a synthetic tissue micro array.
- Clause 6 the method of at least one of clauses 1-5, further comprising: applying a filter material over the cavity; and transferring the cell holder onto a pathology cassette, wherein the pathology cassette is processed to form the synthetic tissue control.
- a method to form a synthetic tissue control for use in determining presence of cancer comprising: co-culturing a plurality of cell culture bags of cells comprising normal cells and cancer cells of a type of cancer based on at least one cell culturing factors, the at least one cell culturing factors comprising a type of the cancer cells being cultured, a ratio of the cancer cells to the normal cells being cultured, and seeding density of the normal cells and the cancer cells being cultured; depositing at least two cell culture bags of co-cultured cells of the plurality of cell culture bags of co-cultured cells in a cavity of a cell holder; processing co-cultured cells from the at least two cell culture bags of co-cultured cells deposited in the cavity; applying an amount of dye to the cavity to identify the co-cultured cells deposited in the cavity during the processing of the co-cultured cells; and forming the synthetic tissue control from the co-cultured cells deposited in the cavity.
- Clause 8 the method of clause 7, wherein co-culturing the plurality of cell culture bags of cells comprises co-culturing the normal cells and the cancer cells in a cell culture chamber configured to maintain a concentration of C0 2 and temperature inside the cell culture chamber at a level based on the at least one cell culturing factors.
- Clause 10 the method of at least one of clauses 7-9, wherein co-culturing the plurality of cell culture bags of cells further comprises culturing the co-cultured cells to provide an expression of markers employed in IHC as diagnostic and as predictive markers for treatment response.
- Clause 11 the method of at least one of clauses 7-9, wherein co-culturing the plurality of cell culture bags of cells further comprises culturing the co-cultured cells to provide an expression of markers employed in IHC as diagnostic markers or as predictive markers for treatment response.
- Clause 12 the method of at least one of clauses 7-9, wherein co-culturing the plurality of cell culture bags of cells further comprises culturing the co-cultured cells to provide a consistent level of expression of RNA and DNA markers when observed via a FISH technique.
- Clause 13 the method of at least one of clauses 7-9, wherein co-culturing the plurality of cell culture bags of cells further comprises culturing the co-cultured cells to provide a consistent level of expression of RNA and DNA markers when observed via a CISH technique.
- Clause 14 the method of at least one of clauses 7-13, further comprising adding DNase to facilitate un-clumping of the normal cells and the cancer cells.
- Clause 15 the method of at least one of clauses 7-14, further comprising: forming a homogenous core with un-clumped normal cells; and invading the homogenous core with un- clumped cells of the cancer cells.
- Clause 16 the method of at least one of clauses 7-15, further comprising adding Fibronectin to facilitate un-clumping of the normal cells and the cancer cells.
- a synthetic tissue microarray comprising: a plurality of synthetic tissue control, each synthetic tissue control of the plurality of synthetic tissue control comprising: normal cells; and cancer cells of a type of cancer, wherein the normal cells and the cancer cells are co-cultured in at least two cell culture bags of a plurality of cell culture bags of co-cultured normal cells and cancer cells, and wherein the plurality of cell culture bags of co-cultured normal cells and the cancer cells are co-cultured based on at least one cell culturing factors comprising a type of the cancer cells being cultured, a ratio of the cancer cells to the normal cells being cultured, seeding density of the normal cells and the cancer cells being cultured, and a type of cell growth supplement used to facilitate culturing the normal cells and cancer cells.
- Clause 18 the synthetic tissue microarray of clause 17, wherein the normal cells and cancer cells are co-cultured to provide a high expression of markers used in IHC or ISH staining.
- Clause 19 the synthetic tissue microarray of clause 17 or 18, wherein the normal cells and cancer cells are co-cultured to provide a medium expression of markers used in IHC or ISH staining.
- Clause 20 the synthetic tissue microarray of at least one of clauses 17-19, wherein the normal cells and cancer cells are co-cultured to provide a low expression of markers used in IHC or ISH staining.
- an "approximately zero gravity environment” is defined to include a zero gravity environment.
- the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise.
- the terms “comprise” and/or “comprising,” when used in this specification and/or the claims, specify the presence of stated features, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, steps, operations, elements, components, and/or groups thereof.
- the steps and components described in the above embodiments and figures are merely illustrative and do not imply that any particular step or component is a requirement of a claimed embodiment.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020501427A JP7727383B2 (ja) | 2017-03-22 | 2018-03-22 | 合成組織対照及び合成組織マイクロアレイ対照の細胞収率 |
| EP18771885.3A EP3601644A4 (en) | 2017-03-22 | 2018-03-22 | CELL YIELD FOR SYNTHETIC TISSUE WITNESSES AND SYNTHETIC MICRO-GRID TISSUE WITNESSES |
| CN201880033316.7A CN110651073A (zh) | 2017-03-22 | 2018-03-22 | 合成组织对照物和合成组织微阵列对照物的细胞收率 |
| CA3057612A CA3057612A1 (en) | 2017-03-22 | 2018-03-22 | Cell yield for synthetic tissue controls and synthetic tissue microarray controls |
| AU2018240361A AU2018240361A1 (en) | 2017-03-22 | 2018-03-22 | Cell yield for synthetic tissue controls and synthetic tissue microarray controls |
| AU2023203396A AU2023203396B2 (en) | 2017-03-22 | 2023-05-31 | Cell yield for synthetic tissue controls and synthetic tissue microarray controls |
| JP2024165854A JP2025000752A (ja) | 2017-03-22 | 2024-09-25 | 合成組織対照及び合成組織マイクロアレイ対照の細胞収率 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/466,421 US20180275027A1 (en) | 2017-03-22 | 2017-03-22 | Cell yield for synthetic tissue controls and synthetic tissue microarray controls |
| US15/466,421 | 2017-03-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2018175774A1 true WO2018175774A1 (en) | 2018-09-27 |
Family
ID=63583360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2018/023840 Ceased WO2018175774A1 (en) | 2017-03-22 | 2018-03-22 | Cell yield for synthetic tissue controls and synthetic tissue microarray controls |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20180275027A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3601644A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7727383B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110651073A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2018240361A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3057612A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018175774A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3126713A1 (fr) * | 2021-09-08 | 2023-03-10 | Erypharm | Procédé de production de cellules de culture à haute densité |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024010921A1 (en) * | 2022-07-08 | 2024-01-11 | Slmp, Llc | Bioengineered and standardized human tissue reference controls for validation of ihc, fish or cish cancer test results |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5153132A (en) * | 1988-06-30 | 1992-10-06 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Three-dimensional co-culture process |
| US5851816A (en) * | 1988-06-30 | 1998-12-22 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Cultured high-fidelity three-dimensional human urogenital tract carcinomas and process |
| US20010055804A1 (en) * | 2000-01-13 | 2001-12-27 | Shekhar Malathy P.V. | Three-dimensional in vitro model of human preneoplastic breast disease |
| US20060148074A1 (en) * | 1996-08-30 | 2006-07-06 | Invitrogen Corporation | Serum-free mammalian cell culture medium, and uses thereof |
| US20110306110A1 (en) * | 2008-12-12 | 2011-12-15 | The University Of Tokyo | Method for three-dimensional hierarchical cell co-culture |
| US20140142370A1 (en) * | 2012-11-16 | 2014-05-22 | The Johns Hopkins University | Platform for Creating an Artificial Blood Brain Barrier |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6190657B1 (en) * | 1995-06-07 | 2001-02-20 | Yale University | Vectors for the diagnosis and treatment of solid tumors including melanoma |
| CN101186899A (zh) * | 2007-10-18 | 2008-05-28 | 天津医科大学 | 一种应用于肿瘤细胞和干细胞共培养的新方法 |
| GB201100180D0 (en) * | 2011-01-06 | 2011-02-23 | Capsant Neurotechnologies Ltd | Tumour cell and tissue culture |
| CN103571792B (zh) * | 2012-07-25 | 2015-11-18 | 中国科学院大连化学物理研究所 | 一种体外扩增肿瘤干细胞的方法 |
| US9617521B2 (en) * | 2013-10-21 | 2017-04-11 | Hemoshear, Llc | In vitro model for a tumor microenvironment |
| US20170307615A1 (en) * | 2014-09-24 | 2017-10-26 | Geisinger Health System | Immunohistochemistry Quality Management Program Using Cultured Cell Lines for Tissue Microarray (TMA) Blocks |
| US10329623B2 (en) * | 2015-08-28 | 2019-06-25 | Slmp, Llc | Synthetic tissue controls and synthetic tissue microarray controls |
-
2017
- 2017-03-22 US US15/466,421 patent/US20180275027A1/en not_active Abandoned
-
2018
- 2018-03-22 EP EP18771885.3A patent/EP3601644A4/en not_active Withdrawn
- 2018-03-22 AU AU2018240361A patent/AU2018240361A1/en not_active Abandoned
- 2018-03-22 JP JP2020501427A patent/JP7727383B2/ja active Active
- 2018-03-22 CN CN201880033316.7A patent/CN110651073A/zh active Pending
- 2018-03-22 WO PCT/US2018/023840 patent/WO2018175774A1/en not_active Ceased
- 2018-03-22 CA CA3057612A patent/CA3057612A1/en not_active Abandoned
-
2023
- 2023-05-31 AU AU2023203396A patent/AU2023203396B2/en active Active
-
2024
- 2024-09-25 JP JP2024165854A patent/JP2025000752A/ja active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5153132A (en) * | 1988-06-30 | 1992-10-06 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Three-dimensional co-culture process |
| US5851816A (en) * | 1988-06-30 | 1998-12-22 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Cultured high-fidelity three-dimensional human urogenital tract carcinomas and process |
| US20060148074A1 (en) * | 1996-08-30 | 2006-07-06 | Invitrogen Corporation | Serum-free mammalian cell culture medium, and uses thereof |
| US20010055804A1 (en) * | 2000-01-13 | 2001-12-27 | Shekhar Malathy P.V. | Three-dimensional in vitro model of human preneoplastic breast disease |
| US20110306110A1 (en) * | 2008-12-12 | 2011-12-15 | The University Of Tokyo | Method for three-dimensional hierarchical cell co-culture |
| US20140142370A1 (en) * | 2012-11-16 | 2014-05-22 | The Johns Hopkins University | Platform for Creating an Artificial Blood Brain Barrier |
Non-Patent Citations (2)
| Title |
|---|
| ANONYMOUS: "ab115347 - Live/Dead Cell Assay", INSTRUCTIONS FOR USE, 2012, pages 1 - 15, XP009519740 * |
| ROCHE DIAGNOSTICS GMBH: "DNase I (Deoxyribonuclease I. E.c. 3.1.21.1) For bovine pancreas Lyophilisate", ROCHE BULLETIN, vol. 11284932001, December 2010 (2010-12-01), pages 1, XP009516764, Retrieved from the Internet <URL:https://web.archive.org/web/20170516194518/https://www.sigmaaldrich.com/content/dam/sigma-aldrich/docs/Roche/Bulletin/1/11284932001bul.pdf> * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3126713A1 (fr) * | 2021-09-08 | 2023-03-10 | Erypharm | Procédé de production de cellules de culture à haute densité |
| WO2023036883A1 (fr) * | 2021-09-08 | 2023-03-16 | Erypharm | Procédé de production de cellules de culture à haute densité |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020515287A (ja) | 2020-05-28 |
| EP3601644A4 (en) | 2020-12-16 |
| CA3057612A1 (en) | 2018-09-27 |
| AU2018240361A1 (en) | 2019-10-31 |
| CN110651073A (zh) | 2020-01-03 |
| US20180275027A1 (en) | 2018-09-27 |
| AU2023203396A1 (en) | 2023-06-29 |
| JP2025000752A (ja) | 2025-01-07 |
| AU2023203396B2 (en) | 2025-11-20 |
| JP7727383B2 (ja) | 2025-08-21 |
| EP3601644A1 (en) | 2020-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023203396B2 (en) | Cell yield for synthetic tissue controls and synthetic tissue microarray controls | |
| Rimm et al. | Amplification of tissue by construction of tissue microarrays | |
| US12110479B2 (en) | Microfluidic devices, systems, and methods for investigating three-dimensional cellular structures | |
| Matossian et al. | In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types | |
| Dannhorn et al. | Morphological and molecular preservation through universal preparation of fresh-frozen tissue samples for multimodal imaging workflows | |
| US12241818B2 (en) | Methods and systems for preparing cytological samples | |
| Johnson et al. | A rapid high throughput bioprinted colorectal cancer spheroid platform for in vitro drug-and radiation-response | |
| Dancau et al. | Tissue microarrays | |
| US20240337569A1 (en) | Apparatus for producing biologic microarray blocks, and method for manufacturing, and usage the same | |
| US10329623B2 (en) | Synthetic tissue controls and synthetic tissue microarray controls | |
| US20240018452A1 (en) | Chip for integrated tumor cell behavior experiments | |
| CN107144456B (zh) | 一种石蜡病理切片组织的水凝胶支撑和脂质清除处理方法 | |
| Chen et al. | Multidimensional coculture system to model lung squamous carcinoma progression | |
| Nielsen et al. | Detection of lncRNA by LNA-based in situ hybridization in paraffin-embedded cancer cell spheroids | |
| HK40019730A (en) | Cell yield for synthetic tissue controls and synthetic tissue microarray controls | |
| US7854899B2 (en) | Template methods and devices for preparing sample arrays | |
| Saremi et al. | Application of tissue microarray in esophageal adenocarcinoma | |
| CN113970472A (zh) | 组织切片方法以及用于组织切片的成型装置 | |
| Nunes et al. | Cell Microarray: An Approach to Evaluate Drug-Induced Alterations in Protein Expression | |
| Zhao et al. | A novel in-situ fixation and embedding method improves lung cancer organoid histopathology | |
| Flint | Multimodal mass spectrometry imaging of an aggregated 3D cell culture model | |
| PL238379B1 (pl) | Urządzenie do perfuzyjnych hodowli komórkowych | |
| CN100392094C (zh) | 细胞及细胞核微阵列制作方法 | |
| Zhu et al. | Optimized pregelatinized starch technique for cell block preparation in cell cultures | |
| Wu et al. | Spatial mapping of the tumor immune microenvironment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18771885 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2020501427 Country of ref document: JP Kind code of ref document: A |
|
| ENP | Entry into the national phase |
Ref document number: 3057612 Country of ref document: CA |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2018771885 Country of ref document: EP Effective date: 20191022 |
|
| ENP | Entry into the national phase |
Ref document number: 2018240361 Country of ref document: AU Date of ref document: 20180322 Kind code of ref document: A |